An Open-Label, Multicenter, Phase 2 Study of CLR 131 in Patients with Relapsed or Refractory (R/R) Select B-Cell Malignancies (CLOVER-1) and Expansion Cohort in Patients with Waldenstrom Macroglobulinemia (CLOVER-WaM)
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
Cellectar Biosciences, Inc.
Start Date
March 9, 2023
End Date
March 31, 2028
Administered By
Duke Cancer Institute
Awarded By
Cellectar Biosciences, Inc.
Start Date
March 9, 2023
End Date
March 31, 2028